Investigator Relationships

Oncology Expertise – Investigator Relationships

Medelis has the right mix of investigator relationships to get your first patients in on time and meet your study timeline. Proper site selection is critical to the success of any oncology study. It’s even more critical in the rapidly expanding area of cancer immunotherapy.

The number one reason why oncology studies fail to meet their enrollment targets boils down to site selection. Determining the right investigator mix that matches your protocol criteria and enrollment timelines is absolutely critical. And it is commonly overlooked.

Having a prestigious academic center in your study can bring valuable recognition, but it can also dramatically affect your enrollment rates if you’re not experienced in working through the administrative hurdles that most larger academic sites present, while also understanding how to keep your study visible among the many other studies running at the site.

Other common causes of delays include:

• Overly restrictive eligibility criteria
• Poor screening practices
• Poor training of on-site personnel
• Not being visible online for the cancer patients to find your study
• Participation fatigue

On overview, to overcome these, sponsors should give extra attention to:

• Truly identifying the right investigator mix that can deliver the right patients to meet the timeline in your protocol
• Improving your communication to investigators, patients and all site staff to keep your study top-of-mind
• Using realistic protocol inclusion/exclusion criteria
• Continually educating patients
• Removing choke points in the patient retention funnel

For a deeper discussion about how to apply these recommendations to your study, feel free to contact us.